IP Library › Granted Patent US 12,441,801
Granted Patent B2
US 12,441,801 · App. 17/325,792 · Granted Oct 14, 2025

Anti-VISTA antibodies and fragments, uses thereof, and methods of identifying same

Inventors: Linda A. Snyder (Pottstown, PA); Gordon Powers (Malvern, PA); Enrique Zudaire Ubani (Ambler, PA); Douglas Matthew Marvel (Lansdale, PA)
Assignee: JANSSEN PHARMACEUTICA NV
C07K16/2827C07K16/2803C07K16/2818A61K2039/507C07K2317/31C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/73C07K2317/732C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,801
App. No.
17/325,792
Granted
Oct 14, 2025
Kind
B2
Abstract

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.

Claims (12)

1. A nucleic acid encoding an antibody or antigen-binding fragment thereof comprising an antigen binding region that binds to a V-domain Ig Suppressor of T cell Activation (VISTA), wherein the encoded antigen binding region of the antibody or antigen binding region comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and which further comprises an antibody VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO:29 and a VL CDR3 having the amino acid sequence of SEQ ID NO:30.

2. The nucleic acid of claim 1 , wherein the encoded antibody or antigen-binding fragment which binds VISTA comprises a VH domain comprising SEQ ID NO:37 and a VL domain comprising SEQ ID NO:44.

3. The nucleic acid of claim 1 , wherein the encoded antibody or antigen-binding fragment which binds VISTA comprises an antibody heavy chain comprising SEQ ID NO:61 and an antibody light chain comprising SEQ ID NO:56.

4. The nucleic acid of claim 1 , wherein the encoded antibody or antigen-binding fragment enhances T cell activation.

5. A recombinant cell which comprises the nucleic acid of claim 1 .

6. A recombinant cell which comprises the nucleic acid of claim 2 .

7. A recombinant cell which comprises the nucleic acid of claim 3 .

8. A recombinant cell which comprises the nucleic acid of claim 4 .

9. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 5 .

10. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 6 .

11. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 7 .

12. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 8 .

Continuity (6)
Division 15481410 · Apr 6, 2017
Continuation In Part 15107784
Provisional Application 62319605 · Apr 7, 2016
Provisional Application 62085086 · Nov 26, 2014
Provisional Application 61920695 · Dec 24, 2013
Related Publication 20210347896A1 · Nov 11, 2021
References Cited (400)
US 4366241A · Tom et al. · 1982 [cited by applicant]
US 4376110A · David et al. · 1983 [cited by applicant]
US 4439196A · Higuchi · 1984 [cited by applicant]
US 4447224A · DeCant, Jr. et al. · 1984 [cited by applicant]
US 4447233A · Mayfield · 1984 [cited by applicant]
US 4475196A · La Zor · 1984 [cited by applicant]
US 4486194A · Ferrara · 1984 [cited by applicant]
US 4487603A · Harris · 1984 [cited by applicant]
US 4517288A · Giegel et al. · 1985 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4699880A · Goldstein · 1987 [cited by applicant]
US 4736866A · Leder et al. · 1988 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4837168A · de Jaeger et al. · 1989 [cited by applicant]
US 4870009A · Evans et al. · 1989 [cited by applicant]
US 4873191A · Wagner et al. · 1989 [cited by applicant]
US 4873316A · Meade et al. · 1989 [cited by applicant]
US 4881175A · Ladner · 1989 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4954617A · Fanger et al. · 1990 [cited by applicant]
US 4987071A · Cech et al. · 1991 [cited by applicant]
US 5013653A · Huston et al. · 1991 [cited by applicant]
US 5064413A · McKinnon et al. · 1991 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5116742A · Cech et al. · 1992 [cited by applicant]
US 5116964A · Capon et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5190878A · Wilhelm · 1993 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5258498A · Huston et al. · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5272071A · Chappel · 1993 [cited by applicant]
US 5283173A · Fields et al. · 1994 [cited by applicant]
US 5283317A · Saifer et al. · 1994 [cited by applicant]
US 5288641A · Roizman · 1994 [cited by applicant]
US 5312335A · McKinnon et al. · 1994 [cited by applicant]
US 5328470A · Nabel et al. · 1994 [cited by applicant]
US 5374548A · Caras · 1994 [cited by applicant]
US 5383851A · McKinnon, Jr. et al. · 1995 [cited by applicant]
US 5399163A · Peterson et al. · 1995 [cited by applicant]
US 5399331A · Loughrey et al. · 1995 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5416016A · Low et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5455030A · Ladner et al. · 1995 [cited by applicant]
US 5476786A · Huston · 1995 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5478925A · Wallach et al. · 1995 [cited by applicant]
US 5482858A · Huston et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5547853A · Wallner et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5580756A · Linsley et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5624659A · Bigner et al. · 1997 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5714350A · Co et al. · 1998 [cited by applicant]
US 5723125A · Chang et al. · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5776427A · Thorpe et al. · 1998 [cited by applicant]
US 5789650A · Lonberg et al. · 1998 [cited by applicant]
US 5811097A · Allison et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5821333A · Carter et al. · 1998 [cited by applicant]
US 5837243A · Deo et al. · 1998 [cited by applicant]
US 5844095A · Linsley et al. · 1998 [cited by applicant]
US 5851795A · Linsley et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5874299A · Lonberg et al. · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 5888807A · Palsson et al. · 1999 [cited by applicant]
US 5922845A · Deo et al. · 1999 [cited by applicant]
US 5932448A · Tso et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5969108A · McCafferty et al. · 1999 [cited by applicant]
US 5985653A · Armstrong et al. · 1999 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6069134A · Roth et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6096532A · Armstrong et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6153737A · Manoharan et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6165745A · Ward et al. · 2000 [cited by applicant]
US 6172197B1 · McCafferty et al. · 2001 [cited by applicant]
US 6172208B1 · Cook · 2001 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6187287B1 · Leung et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6300319B1 · Manoharan · 2001 [cited by applicant]
US 6335434B1 · Guzaev et al. · 2002 [cited by applicant]
US 6335437B1 · Manoharan · 2002 [cited by applicant]
US 6350861B1 · Co et al. · 2002 [cited by applicant]
US 6395437B1 · Wollesen · 2002 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6444806B1 · Veerapanani et al. · 2002 [cited by applicant]
US 6486308B2 · Kutyavin et al. · 2002 [cited by applicant]
US 6492123B1 · Holliger et al. · 2002 [cited by applicant]
US 6521404B1 · Griffiths et al. · 2003 [cited by applicant]
US 6525031B2 · Manoharan · 2003 [cited by applicant]
US 6528631B1 · Cook et al. · 2003 [cited by applicant]
US 6544731B1 · Griffiths et al. · 2003 [cited by applicant]
US 6545170B2 · Pitzele et al. · 2003 [cited by applicant]
US 6548640B1 · Winter · 2003 [cited by applicant]
US 6555313B1 · Griffiths et al. · 2003 [cited by applicant]
US 6559279B1 · Manoharan et al. · 2003 [cited by applicant]
US 6562576B2 · Manfredi · 2003 [cited by applicant]
US 6582915B1 · Griffiths et al. · 2003 [cited by applicant]
US 6586474B2 · Webber et al. · 2003 [cited by applicant]
US 6591889B2 · Bettio et al. · 2003 [cited by applicant]
US 6593081B1 · Griffiths et al. · 2003 [cited by applicant]
US 6593372B2 · Enikolopov et al. · 2003 [cited by applicant]
US 6632927B2 · Adair et al. · 2003 [cited by applicant]
US 6639055B1 · Carter et al. · 2003 [cited by applicant]
US 6653104B2 · Goldenberg · 2003 [cited by applicant]
US 6696686B1 · Wainer et al. · 2004 [cited by applicant]
US 6790624B2 · Mayer · 2004 [cited by applicant]
US 6809117B2 · Enikolopov et al. · 2004 [cited by applicant]
US 6818418B1 · Lipovsek et al. · 2004 [cited by applicant]
US 6924355B2 · Baker et al. · 2005 [cited by applicant]
US 6936436B2 · Baker et al. · 2005 [cited by applicant]
US 6936697B2 · Desnoyers et al. · 2005 [cited by applicant]
US 6982323B1 · Wang et al. · 2006 [cited by applicant]
US 7026448B2 · Baker et al. · 2006 [cited by applicant]
US 7049058B2 · Singh · 2006 [cited by applicant]
US 7196118B2 · Webber et al. · 2007 [cited by applicant]
US 7226759B2 · Sun · 2007 [cited by applicant]
US 7250297B1 · Beste et al. · 2007 [cited by applicant]
US 7488802B2 · Collins et al. · 2009 [cited by applicant]
US 7595048B2 · Honjo · 2009 [cited by applicant]
US 7655778B2 · Yang · 2010 [cited by applicant]
US 7919585B2 · Chen · 2011 [cited by applicant]
US 8119117B2 · Deisseroth et al. · 2012 [cited by applicant]
US 8231872B2 · Noelle et al. · 2012 [cited by applicant]
US 8236304B2 · Noelle et al. · 2012 [cited by applicant]
US 8465740B2 · Noelle et al. · 2013 [cited by applicant]
US 8501915B2 · Noelle et al. · 2013 [cited by applicant]
US 8652465B2 · Freeman · 2014 [cited by applicant]
US 9217035B2 · Noelle et al. · 2015 [cited by applicant]
US 9381244B2 · Noelle et al. · 2016 [cited by applicant]
US 9631018B2 · Noelle et al. · 2017 [cited by applicant]
US 9879092B2 · Laury-Kleintop et al. · 2018 [cited by applicant]
US 9890215B2 · Noelle et al. · 2018 [cited by applicant]
US 10035857B2 · Noelle et al. · 2018 [cited by applicant]
US 10273301B2 · Snyder et al. · 2019 [cited by applicant]
US 10370455B2 · Molloy et al. · 2019 [cited by applicant]
US 10745467B2 · Noelle et al. · 2020 [cited by applicant]
US 10822423B2 · Noelle · 2020 [cited by applicant]
US 10899836B2 · Snyder et al. · 2021 [cited by applicant]
US 11009509B2 · Snyder · 2021 [cited by examiner]
US 11014987B2 · Snyder · 2021 [cited by examiner]
US 11180557B2 · Noelle et al. · 2021 [cited by applicant]
US 11242392B2 · Snyder · 2022 [cited by examiner]
US 11525000B2 · Molloy · 2022 [cited by examiner]
US 11603402B2 · Carriere · 2023 [cited by examiner]
US 11603403B2 · Lemercier · 2023 [cited by examiner]
US 11649283B2 · Molloy · 2023 [cited by examiner]
US 11987630B2 · Snyder · 2024 [cited by examiner]
US 12139532B2 · Rothstein · 2024 [cited by examiner]
US 12188938B2 · Snyder · 2025 [cited by examiner]
US 20030031671A1 · Welt et al. · 2003 [cited by applicant]
US 20030054406A1 · Baker et al. · 2003 [cited by applicant]
US 20040110704A1 · Yamane et al. · 2004 [cited by applicant]
US 20040132028A1 · Stumpp et al. · 2004 [cited by applicant]
US 20040132101A1 · Lazar et al. · 2004 [cited by applicant]
US 20040259209A1 · Sun et al. · 2004 [cited by applicant]
US 20050043519A1 · Dooley et al. · 2005 [cited by applicant]
US 20050063948A1 · Dickerson et al. · 2005 [cited by applicant]
US 20060025576A1 · Miller et al. · 2006 [cited by applicant]
US 20060034852A1 · Rixon et al. · 2006 [cited by applicant]
US 20060084082A1 · Ruben et al. · 2006 [cited by applicant]
US 20070092512A1 · Daaka et al. · 2007 [cited by applicant]
US 20070122378A1 · Freeman et al. · 2007 [cited by applicant]
US 20070148167A1 · Stohl · 2007 [cited by applicant]
US 20070224633A1 · Skerra et al. · 2007 [cited by applicant]
US 20080069820A1 · Fuh et al. · 2008 [cited by applicant]
US 20080139791A1 · Lipovsek et al. · 2008 [cited by applicant]
US 20080166353A1 · Cherwinski · 2008 [cited by applicant]
US 20080248007A1 · Chen · 2008 [cited by applicant]
US 20080287358A1 · Noelle et al. · 2008 [cited by applicant]
US 20090215991A1 · Lazar et al. · 2009 [cited by applicant]
US 20100316639A1 · Lackner · 2010 [cited by applicant]
US 20100317834A1 · Lazar et al. · 2010 [cited by applicant]
US 20110027278A1 · Noelle et al. · 2011 [cited by applicant]
US 20110158995A1 · Tan et al. · 2011 [cited by applicant]
US 20110206699A1 · Hossain et al. · 2011 [cited by applicant]
US 20110223188A1 · Langermann · 2011 [cited by applicant]
US 20110243942A1 · Wang · 2011 [cited by applicant]
US 20120195894A1 · Noelle et al. · 2012 [cited by applicant]
US 20130177557A1 · Noelle et al. · 2013 [cited by applicant]
US 20140037634A1 · Noelle et al. · 2014 [cited by applicant]
US 20140056890A1 · Gurney et al. · 2014 [cited by applicant]
US 20140056892A1 · Noelle et al. · 2014 [cited by applicant]
US 20140105912A1 · Noelle et al. · 2014 [cited by applicant]
US 20140220012A1 · Noelle et al. · 2014 [cited by applicant]
US 20140227279A1 · Laury-Kleintop et al. · 2014 [cited by applicant]
US 20140341920A1 · Noelle et al. · 2014 [cited by applicant]
US 20150231215A1 · Noelle et al. · 2015 [cited by applicant]
US 20160008316A1 · Bacha et al. · 2016 [cited by applicant]
US 20160083472A1 · Noelle et al. · 2016 [cited by applicant]
US 20160096891A1 · Chen et al. · 2016 [cited by applicant]
US 20160159927A1 · Molloy et al. · 2016 [cited by applicant]
US 20160168248A1 · Noelle et al. · 2016 [cited by applicant]
US 20160318999A9 · Noelle et al. · 2016 [cited by applicant]
US 20160331803A1 · Noelle et al. · 2016 [cited by applicant]
US 20170051061A1 · Snyder et al. · 2017 [cited by applicant]
US 20170119877A1 · Green et al. · 2017 [cited by applicant]
US 20170233479A1 · Snyder et al. · 2017 [cited by applicant]
US 20170334990A1 · Noelle et al. · 2017 [cited by applicant]
US 20180051070A1 · Noelle et al. · 2018 [cited by applicant]
US 20180079811A1 · Molloy et al. · 2018 [cited by applicant]
US 20180215826A1 · Noelle et al. · 2018 [cited by applicant]
US 20200017589A1 · Snyder et al. · 2020 [cited by applicant]
US 20210017281A1 · Molloy et al. · 2021 [cited by applicant]
US 20210317206A1 · Molloy et al. · 2021 [cited by applicant]
US 20210317207A1 · Noelle et al. · 2021 [cited by applicant]
US 20220144954A1 · Snyder · 2022 [cited by examiner]
US 20240018238A1 · Molloy · 2024 [cited by examiner]
US 20240067719A1 · Molloy · 2024 [cited by examiner]
US 20240141037A1 · Carriere · 2024 [cited by examiner]
CA 2383456 · 2001 [cited by applicant]
CN 1753912 · 2006 [cited by applicant]
EP 0045665 · 1982 [cited by applicant]
EP 0125023 · 1984 [cited by applicant]
EP 0154316 · 1985 [cited by applicant]
EP 0171496 · 1986 [cited by applicant]
EP 0173494 · 1986 [cited by applicant]
EP 0184187 · 1986 [cited by applicant]
EP 0264166 · 1988 [cited by applicant]
EP 0401384 · 1990 [cited by applicant]
EP 1176195 · 2002 [cited by applicant]
EP 1641818 · 2006 [cited by applicant]
JP 08506635 · 2008 [cited by applicant]
WO WO00045665 · 1982 [cited by applicant]
WO WO86001533 · 1986 [cited by applicant]
WO WO87002671 · 1987 [cited by applicant]
WO WO87005330 · 1987 [cited by applicant]
WO WO88000052 · 1988 [cited by applicant]
WO WO88009810 · 1988 [cited by applicant]
WO WO89010134 · 1989 [cited by applicant]
WO WO91006667 · 1991 [cited by applicant]
WO WO92003918 · 1992 [cited by applicant]
WO WO93008829 · 1993 [cited by applicant]
WO WO93012227 · 1993 [cited by applicant]
WO WO94010300 · 1994 [cited by applicant]
WO WO94010332 · 1994 [cited by applicant]
WO WO94025585 · 1994 [cited by applicant]
WO WO94029351 · 1994 [cited by applicant]
WO WO94029436 · 1994 [cited by applicant]
WO WO97007668 · 1997 [cited by applicant]
WO WO97007669 · 1997 [cited by applicant]
WO WO97013852 · 1997 [cited by applicant]
WO WO97028267 · 1997 [cited by applicant]
WO WO98024884 · 1998 [cited by applicant]
WO WO99045962 · 1999 [cited by applicant]
WO WO99054342 · 1999 [cited by applicant]
WO WO00006593 · 2000 [cited by applicant]
WO WO00029004 · 2000 [cited by applicant]
WO WO00031113 · 2000 [cited by applicant]
WO WO00042072 · 2000 [cited by applicant]
WO WO01000814 · 2001 [cited by applicant]
WO WO01003737 · 2001 [cited by applicant]
WO WO01014424 · 2001 [cited by applicant]
WO WO02029072 · 2002 [cited by applicant]
WO WO02043478 · 2002 [cited by applicant]
WO WO02079449 · 2002 [cited by applicant]
WO WO02092780 · 2002 [cited by applicant]
WO WO03035835 · 2003 [cited by applicant]
WO WO03074679 · 2003 [cited by applicant]
WO WO04018520 · 2004 [cited by applicant]
WO WO04037999 · 2004 [cited by applicant]
WO WO05056764 · 2005 [cited by applicant]
WO WO05112834 · 2005 [cited by applicant]
WO WO05113606 · 2005 [cited by applicant]
WO WO06012232 · 2006 [cited by applicant]
WO WO06050247 · 2006 [cited by applicant]
WO WO06050262 · 2006 [cited by applicant]
WO WO06116181 · 2006 [cited by applicant]
WO WO07030198 · 2007 [cited by applicant]
WO WO08098796 · 2008 [cited by applicant]
WO WO09089004 · 2009 [cited by applicant]
WO WO10027827 · 2010 [cited by applicant]
WO WO11120013 · 2011 [cited by applicant]
WO WO2011120013A2 · 2011 [cited by applicant]
WO WO13184912 · 2013 [cited by applicant]
WO WO13192504 · 2013 [cited by applicant]
WO WO2013192504A1 · 2013 [cited by applicant]
WO WO14039983 · 2014 [cited by applicant]
WO WO2014039983A1 · 2014 [cited by applicant]
WO WO14190356 · 2014 [cited by applicant]
WO WO2014190356A2 · 2014 [cited by applicant]
WO WO2014197849A2 · 2014 [cited by applicant]
WO WO15097536 · 2015 [cited by applicant]
WO WO15109340 · 2015 [cited by applicant]
WO WO2015097536A2 · 2015 [cited by applicant]
WO WO15191881 · 2015 [cited by applicant]
WO WO16090347 · 2016 [cited by applicant]
WO WO2016207717 · 2016 [cited by applicant]
WO WO17181109 · 2017 [cited by applicant]
WO WO17181139 · 2017 [cited by applicant]
WO WO18027042 · 2018 [cited by applicant]
Aalberse RC, et al. “lgG4 breaking the rules,” Immunology. Jan. 2002;105(1):9-19. [cited by applicant]
Adriouch S, et al. “Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer,” Front Microbiol. Sep. 29, 2011;2:199. [cited by applicant]
Allen, et al., (2009), “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis”, Biochemistry, 48(17), 3755-3766. [cited by applicant]
Allen, T. M. “Ligand-targeted therapeutics in anticancer therapy,” Nat Rev Cancer. Oct. 2002;2(10):750-63. [cited by applicant]
Almquist RG, et al. “Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme,” J Med Chem. Dec. 1980;23(12):1392-8. [cited by applicant]
Al-Obeidi F, et al. “Peptide and peptidomimetic libraries. Molecular diversity and drug design,” Mol Biotechnol. Jun. 1998;9(3):205-23. [cited by applicant]
Altman JD, et al. “Phenotypic analysis of antigen-specific T lymphocytes,” Science. Oct. 4, 1996;274(5284):94-6. [cited by applicant]
Altschul SF, et al. “Basic local alignment search tool,” J Mol Biol. Oct. 5, 1990;215(3):403-10. [cited by applicant]
Altschul SF, et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402. [cited by applicant]
Amancha PK, et al. “In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit,” J Immunol. Dec. 15, 2013;191(12):6… [cited by applicant]
Ansari MJ, et al. “The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice,” J Exp Med. Jul. 7, 2003;198(1):63-9. [cited by applicant]
Arkin AP, et al. “An algorithm for protein engineering: simulations of recursive ensemble mutagenesis,” Proc Natl Acad Sci U S A. Aug. 15, 1992;89(16):7811-5. [cited by applicant]
Attia, P., et al., Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol, 2005. 23(25): p. 6043-53. [cited by applicant]
Auffray, C et al. “Blood monocytes: development, heterogeneity, and relationship with dendritic cells,” Annu Rev Immunol, 2009. 27: p. 669-92. [cited by applicant]
Bagley RG, et al. “sFLT01: a novel fusion protein with antiangiogenic activity,” Mol Cancer Ther. Mar. 2011;10(3):404-15. [cited by applicant]
Bak, S. P., et al., Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol, 2008. 46(2): p. 258-68. [cited by applicant]
Baldari C, et al. “A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in [cited by applicant]
Banerji J, et al. “A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes,” Cell. Jul. 1983;33(3):729-40. [cited by applicant]
Barringer KJ, et al. “Blunt-end and single-strand ligations by [cited by applicant]
Bartel DP, et al. “Isolation of new ribozymes from a large pool of random sequences,” Science. Sep. 10, 1993;261(5127):1411-8. [cited by applicant]
Baskar S, et al. “Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules,” Proc Natl Acad Sci U S A. Jun. 15, 1993;90(12):5687-90. [cited by applicant]
Batzer MA, et al. “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus,” Nucleic Acids Res. Sep. 25, 1991;19(18):5081. [cited by applicant]
Bauer S, et al. “Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo,” Cancer Res. Apr. 15, 1999;59(8):1961-5. [cited by applicant]
Beidler CB, et al. “Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen,” J Immunol. Dec. 1, 1988;141(11):4053-60. [cited by applicant]
Beilharz MW, et al. “Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression,” J Immunol. Apr. 15, 2004;172(8):4917-25. [cited by applicant]
Belousov ES, et al. “Sequence-specific targeting and covalent modification of human genomic DNA,” Nucleic Acids Res. Sep. 1, 1997;25(17):3440-4. [cited by applicant]
Béranger F, et al. “Getting more from the two-hybrid system: N-terminal fusions to LexA are efficient and sensitive baits for two-hybrid studies,” Nucleic Acids Res. May 15, 1997;25(10):2035-6. [cited by applicant]
Berge SM, et al. “Pharmaceutical salts,” J Pharm Sci. Jan. 1977;66(1):1-19. [cited by applicant]
Berney C, et al. “A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein,” J Exp Med. Sep. 20, 1999;190(6):851-60. [cited by applicant]
Better M, et al. “ [cited by applicant]
Bird RE, et al. “Single-chain antigen-binding proteins,” Science. Oct. 21, 1988;242(4877):423-6. [cited by applicant]
Blank C, et al. “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,” Cancer Immunol Immunother. Apr. 2005;54(4):307-14. [cited by applicant]
Blank, C., et al., “PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells,” Cancer Res, 2004. 64(3): p. 1140-5. [cited by applicant]
Blazar et al., “Infusion of anti-B7. 1 (CD80) and anti-B7. 2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.” The Journal of Immunolo… [cited by applicant]
Bloemen PG, et al. “Adhesion molecules: a new target for immunoliposome-mediated drug delivery,” FEBS Lett. Jan. 3, 1995;357(2):140-4. [cited by applicant]
Blommers MJ, et al. “Effects of the introduction of L-nucleotides into DNA. Solution structure of the heterochiral duplex d(G-C-G-(L)T-G-C-G).d(C-G-C-A-C-G-C) studied by NMR spectroscopy,” Biochemistry. Jun. 28, 1994;33… [cited by applicant]
Bluestone JA, et al. “Natural versus adaptive regulatory T cells,” Nat Rev Immunol. Mar. 2003;3(3):253-7. [cited by applicant]
Bogdan C. “Nitric oxide and the immune response,” Nat Immunol. Oct. 2001;2(10):907-16. [cited by applicant]
Bolhassani, A. et al., “Improvement of different vacine delivery systems for cancer therapy”, Molecular Cancer, 2011, vol. 10, No. 1, Article No. 3. [cited by applicant]
Boon T, et al. “Human T cell responses against melanoma,” Annu. Rev. Immunol.. Apr. 23, 2006;24:175-208. [cited by applicant]
Borriello F, et al. “B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation,” Immunity. Mar. 1997;6(3):303-13. [cited by applicant]
Borrok MJ, “pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling,” The Journal of Biological Chemistry. 2015;290(7):4282-90. [cited by applicant]
Boulianne GL, et al. “Production of functional chimaeric mouse/human antibody,” Nature. Dec. 13-19, 1984;312(5995):643-6. [cited by applicant]
Bowen JL, et al. “Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease,” J Immunol. Dec. 1, 2009;183(11):6971-80. [cited by applicant]
Brahmer, J. R., et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 2010. 28(19): p… [cited by applicant]
Brandt C, et al. “The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans,” J Exp Med. Jul. 6, 2009;206(7):1495-503. [cited by applicant]
Brennan M, et al. “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments,” Science. Jul. 5, 1985;229(4708):81-3. [cited by applicant]
Briscoe P, et al. “Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes,” Am J Physiol. Mar. 1995;268(3 Pt 1):L374-80. [cited by applicant]
Brisson, et al. “Expression of a bacterial gene in plants by using a viral vector,” Nature vol. 310 Aug. 1984, 511-14. [cited by applicant]
Broglie R, et al. “Light-regulated expression of a pea ribulose-1,5-bisphosphate carboxylase small subunit gene in transformed plant cells,” Science. May 25, 1984;224(4651):838-43. [cited by applicant]
Brown JP, et al. “Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies,” J Biol Chem. Jun. 10, 1980;255(11):4980-3. [cited by applicant]
Brown JP, et al. “Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies,” J Immunol. Aug. 1981; 127(2):539-46. [cited by applicant]
Brys L, et al. “Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection,” J Immunol. May 15, 2005;174(10):6… [cited by applicant]
Burg JL, et al. “Single molecule detection of RNA reporter probes by amplification with Q beta replicase,” Mol Cell Probes. Aug. 1996;10(4):257-71. [cited by applicant]
Butte MJ, et al. “Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses,” Immunity. Jul. 2007;27(1):111-22. [cited by applicant]
Byrne GW, et al. “Multiplex gene regulation: a two-tiered approach to transgene regulation in transgenic mice,” Proc Natl Acad Sci U S A. Jul. 1989;86(14):5473-7. [cited by applicant]
Cabilly S, et al. “Generation of antibody activity from immunoglobulin polypeptide chains produced in [cited by applicant]
Cabilly S, et al. “Immunoglobulin transcripts and molecular history of a hybridoma that produces antibody to carcinoembryonic antigen,” Gene. 1985;40(1):157-61. [cited by applicant]
Calabro, L., et al., “Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications,” Semin Oncol, 2010. 37(5): p. 460-7. [cited by applicant]
Calame K, et al. “Transcriptional controlling elements in the immunoglobulin and T cell receptor loci,” Adv Immunol. 1988;43:235-75. [cited by applicant]
Camper SA, et al. “Postnatal repression of the alpha-fetoprotein gene is enhancer independent,” Genes Dev. Apr. 1989;3(4):537-46. [cited by applicant]
Cancer Prevention Overview (PDQ®), PDQ Cancer Information Summaries [Internet].2017, 14 pages. [cited by applicant]
Carell, et al. “A Solution-Phase Screening Procedure for the Isolation of Active Compounds from a Library of Molecules,” Angew. Chem. Int. Ed. Engl. 1994, 33. No. 20, 2061-64. [cited by applicant]
Carter L, et al. “PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2,” Eur J Immunol. Mar. 2002;32(3):634-43. [cited by applicant]
Ceeraz S, et al. “VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis,” Arthritis Rheumatol. Apr. 2017;69(4):814-825. [cited by applicant]
Chambers CA, et al. “Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells,” Immunity. Dec. 1997;7(6):885-95. [cited by applicant]
Chan AC, et al. “Therapeutic antibodies for autoimmunity and inflammation,” Nat Rev Immunol. May 2010;10(5):301-16. [cited by applicant]
Chen J, et al. “B cell development in mice that lack one or both immunoglobulin kappa light chain genes,” EMBO J. Mar. 1993;12(3):821-30. [cited by applicant]
Chen J, et al. “Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus,” Int Immunol. Jun. 1993;5(6):647-56. [cited by applicant]
Chen L, et al. “Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4,” Cell. Dec. 24, 1992;71(7):1093-102. [cited by applicant]
Chen S, et al. “Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus,” Clin Exp Immunol. Oct. 2011;166(1):134-42. [cited by applicant]
Chen SH, et al. “Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo,” Proc Natl Acad Sci U S A. Apr. 12, 1994;91(8):3054-7. [cited by applicant]
Chen, Y., “Development of a sandwich ELISA for evaluating soluble Pd-Li (CD274) in human sera of different ages as well as supernatants of PD-L1(+) cell lines,” Cytokine 2011. [cited by applicant]
Cho CY, et al. “An unnatural biopolymer,” Science. Sep. 3, 1993;261(5126):1303-5. [cited by applicant]
Choi TK, et al. “Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome,” Nat Genet. Jun. 1993;4(2):117-23. [cited by applicant]